Innoviva (INVA) Short term Debt (2010 - 2025)

Innoviva's (INVA) quarterly Short term Debt came in at $191.9 million in Q2 2025, little changed on a QoQ basis from $192.2 million in Q1 2025.

Innoviva (INVA) Short term Debt (2010 - 2025) Analysis & Trends

Innoviva (INVA) has 10 years of Short term Debt data on file, last reported at $191.9 million in Q2 2025.

Quarterly Short term Debt changed N/A year-over-year to $191.9 million in Q2 2025, while the trailing twelve-month figure through Jun 2025 was $191.9 million (changed N/A YoY) and the FY2024 annual result came in at $192.0 million, changed N/A from the prior year.
Short term Debt held at $191.9 million in Q2 2025, from $192.2 million in the prior quarter.
In the past five years, Short term Debt ranged from a high of $192.2 million in Q1 2025 to a low of $96.0 million in Q1 2022.
A 3-year average of $144.1 million and a median of $144.0 million in 2022 frame the typical range for Short term Debt.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn
4	Revolution Medicines	43.64 Bn	43.64 Bn	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn
7	Royalty Pharma	33.72 Bn	35.84 Bn	-
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn
10	Innoviva	1.54 Bn	968.79 Mn	90.62 Mn

Download Data